Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CDXS

Codexis Inc

Apr 23 • 01:01PM ET

2.39

-0.08 -3.04 %

Healthcare • Biotechnology • USA • NASD

Peers: TSN DSM BIOX REGN INVA SGMO AVIR DVAX VNRX DTIL

| Held by: IWM VTI IBB IWO VXF VTWO IWC FESM IWN PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.52	Insider Own	8.01%	Shs Outstand	90.48M	Perf Week	-5.71%
Market Cap	217.63M	Forward P/E	-	EPS next Y	-0.36	Insider Trans	-15.70%	Shs Float	83.59M	Perf Month	43.41%
Enterprise Value	212.15M	PEG	-	EPS next Q	-0.15	Inst Own	73.71%	Short Float	8.30%	Perf Quarter	30.87%
Income	-43.97M	P/S	3.09	EPS this Y	13.60%	Inst Trans	7.91%	Short Ratio	2.90	Perf Half Y	-13.22%
Sales	70.39M	P/B	4.29	EPS next Y	16.67%	ROA	-29.63%	Short Interest	6.94M	Perf YTD	46.93%
Book/sh	0.56	P/C	2.77	EPS next 5Y	19.59%	ROE	-74.88%	52W High	3.87 -38.11%	Perf Year	5.04%
Cash/sh	0.87	P/FCF	-	EPS past 3/5Y	0.62% -4.52%	ROIC	-36.40%	52W Low	0.96 149.92%	Perf 3Y	-44.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-20.22% 0.38%	Gross Margin	79.49%	Volatility	7.32% 8.31%	Perf 5Y	-90.05%
Dividend TTM	-	EV/Sales	3.01	EPS Y/Y TTM	42.63%	Oper. Margin	-54.46%	ATR (14)	0.17	Perf 10Y	-30.98%
Dividend Ex-Date	-	Quick Ratio	3.75	Sales Y/Y TTM	18.61%	Profit Margin	-62.47%	RSI (14)	63.05	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	3.82	EPS Q/Q	182.76%	SMA20	11.85%	Beta	2.35	Target Price	6.10
Payout	-	Debt/Eq	1.45	Sales Q/Q	81.34%	SMA50	46.23%	Rel Volume	0.28	Prev Close	2.47
Employees	146	LT Debt/Eq	1.39	Earnings	Mar 11 AMC	SMA200	15.37%	Avg Volume	2.39M	Price	2.39
IPO	Apr 22, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	466.67% 8.61%	Trades		Volume	375,062	Change	-3.04%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-24	Downgrade	The Benchmark Company	Buy → Hold
Jun-03-24	Resumed	Jefferies	Buy	$5
May-30-24	Initiated	Cantor Fitzgerald	Overweight	$11
Feb-29-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-07-23	Downgrade	The Benchmark Company	Buy → Hold
Aug-07-23	Downgrade	TD Cowen	Outperform → Market Perform	$21 → $4
May-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Resumed	Piper Sandler	Overweight	$35
Mar-02-22	Resumed	Cowen	Outperform
Apr-12-21	Initiated	Piper Sandler	Overweight	$32
Mar-01-21	Initiated	Stifel	Buy	$30
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$21 → $26
Mar-10-20	Initiated	The Benchmark Company	Buy
Jan-17-19	Upgrade	First Analysis Sec	Neutral → Outperform	$12 → $19
May-16-18	Initiated	Stephens	Overweight	$16
Oct-13-17	Reiterated	H.C. Wainwright	Buy	$8 → $8.50
May-31-17	Initiated	Jefferies	Buy	$8
Jan-26-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight	$5.50
Jan-04-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-06-16	Initiated	H.C. Wainwright	Buy	$6

Show Previous Ratings

Today 09:00AM	Codexis to Report First Quarter 2026 Financial Results on May 7 (GlobeNewswire)
Mar-11-26 11:01PM	Codexis Inc (CDXS) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com) +34.65%
08:15PM	Codexis, Inc. Q4 2025 Earnings Call Summary (Moby)
04:37PM	Codexis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results (GlobeNewswire)
08:03PM	Loading…
Mar-07-26 08:03PM	Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf (MarketBeat)
Mar-05-26 07:45AM	Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks) +16.67%
Mar-04-26 10:06AM	Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform (PR Newswire) +10.20%
Feb-26-26 09:55AM	Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-25-26 09:00AM	Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11 (GlobeNewswire)
Feb-24-26 08:50AM	Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-17-26 09:00AM	Codexis to Participate in TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-10-26 09:00AM	Codexis Achieves ISO 9001:2015 Certification (GlobeNewswire)
08:15AM	Incyte (INCY) Q4 Earnings Lag Estimates (Zacks)
Jan-07-26 09:00AM	Codexis Expands Reach of the ECO Synthesis Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics (PR Newswire)
09:35AM	Loading…
Nov-11-25 09:35AM	Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS) (Zacks)
Nov-10-25 09:00AM	Codexis Announces Signing of Lease for GMP Manufacturing Facility (GlobeNewswire)
Nov-07-25 12:02AM	Codexis Inc (CDXS) Q3 2025 Earnings Call Highlights: Strategic Shifts and New Partnerships ... (GuruFocus.com) -16.95%
Nov-06-25 08:00PM	Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.35%
06:55PM	Codexis: Q3 Earnings Snapshot (Associated Press Finance)
04:21PM	Codexis Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-29-25 09:58AM	Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing (PR Newswire) -6.56%
Oct-23-25 07:05AM	Codexis to Report Third Quarter 2025 Financial Results on November 6 (GlobeNewswire)
Aug-28-25 09:00AM	Codexis to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-25 03:12AM	Codexis Inc (CDXS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Initiatives (GuruFocus.com)
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.64%
04:23PM	Codexis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Second Quarter 2025 Financial Results (GlobeNewswire)
07:30AM	Loading…
07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-12-25 03:00PM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 07:30AM	Switch Bioworks Expands Leadership Team and Moves into New Facility to Accelerate Development of its Microbial Fertilizer Products (PR Newswire)
Aug-04-25 05:15PM	Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +5.58%
Aug-01-25 07:45AM	Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 04:05PM	Codexis to Report Second Quarter 2025 Financial Results on August 13 (GlobeNewswire)
May-22-25 07:00AM	Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA (GlobeNewswire) +5.13%
May-21-25 04:05PM	Codexis to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 01:03PM	Q1 2025 Codexis Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ... (GuruFocus.com)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Codexis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.32%
May-07-25 07:00AM	Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting (GlobeNewswire)
Apr-30-25 04:05PM	Codexis to Report First Quarter 2025 Financial Results on May 14 (GlobeNewswire)
Apr-24-25 10:01AM	Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-09-25 05:00PM	Codexis Announces Byron Dorgan to Retire from Board of Directors (GlobeNewswire) +17.26%
Apr-03-25 10:01AM	Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? (Zacks) -8.03%
Apr-01-25 07:00AM	Codexis Appoints Cynthia Collins to Board of Directors (GlobeNewswire) -6.69%
Mar-24-25 07:00AM	Codexis Announces First Revenue-Generating Contract for ECO Synthesis Manufacturing Services (GlobeNewswire) +20.39%
Mar-07-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -6.74%
Feb-28-25 11:02AM	Q4 2024 Codexis Inc Earnings Call (Thomson Reuters StreetEvents) -22.65%
02:36AM	Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ... (GuruFocus.com)
Feb-27-25 06:35PM	Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.53%
05:36PM	Codexis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 04:05PM	Codexis to Participate in TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-14-25 05:15PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +5.12%
Feb-13-25 04:05PM	Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th (GlobeNewswire)
Feb-06-25 04:05PM	Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board (GlobeNewswire)
Jan-16-25 04:05PM	Codexis Appoints Christos Richards to Board of Directors (GlobeNewswire)
Jan-10-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -7.77%
Dec-06-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +15.22%
Nov-19-24 04:05PM	Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +8.14%
Nov-14-24 04:05PM	Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics (GlobeNewswire) -7.43%
Nov-12-24 04:05PM	Codexis Announces Appointment of Raymond De Vre, PhD, to Board of Directors (GlobeNewswire)
04:05PM	Codexis Announces Appointment of Raymond De Vr , PhD, to Board of Directors (GlobeNewswire)
Nov-11-24 04:05PM	Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics (GlobeNewswire)
Nov-08-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Nov-04-24 04:05PM	Codexis to Participate in Upcoming Healthcare Conferences (GlobeNewswire) +9.46%
Nov-01-24 09:01AM	Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... (GuruFocus.com) +11.46%
Oct-31-24 05:30PM	Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Codexis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-24-24 04:05PM	Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) -7.27%
Oct-15-24 07:10AM	Codexis announces employment inducement grants (TipRanks) +5.28%
Oct-14-24 07:05AM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Oct-10-24 04:05PM	Codexis to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire) +6.06%
Oct-09-24 05:56PM	Codexis Inc (CDXS) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
Oct-02-24 04:05PM	Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company (GlobeNewswire)
Oct-01-24 07:05AM	Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences (GlobeNewswire)
Sep-26-24 01:01PM	Casdin Capital, LLC Increases Stake in Codexis Inc (GuruFocus.com) +6.53%
Sep-24-24 01:03AM	Opaleye Management Inc. Expands Stake in Codexis Inc. (GuruFocus.com)
Sep-20-24 02:25AM	Opaleye Management Inc. Increases Stake in Codexis Inc. (GuruFocus.com)
Sep-06-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Sep-03-24 04:05PM	Codexis to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-20-24 04:05PM	Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting (GlobeNewswire)
Aug-16-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Aug-15-24 04:05PM	Codexis Publishes FY2023 Sustainability Disclosures (GlobeNewswire)
Aug-08-24 05:55PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -11.11%
04:51PM	Codexis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-18-24 04:05PM	Codexis to Report Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) +7.58%
Jul-10-24 01:30PM	Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc. (PR Newswire)
Jul-03-24 07:37AM	Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit (BioPharma Dive)

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lutz Stefan	Chief Scientific Officer	Feb 24 '26	Sale	1.13	5,862	6,641	130,421	Feb 25 07:54 PM
Lutz Stefan	Officer	Feb 24 '26	Proposed Sale	1.17	5,280	6,178		Feb 23 08:08 PM
Lutz Stefan	Chief Scientific Officer	Feb 06 '26	Sale	1.31	2,492	3,257	136,283	Feb 09 04:07 PM
Erbez Georgia	See Remarks	Feb 06 '26	Sale	1.31	3,826	5,001	66,810	Feb 09 04:07 PM
MOORE ALISON	President and CEO	Feb 06 '26	Sale	1.31	3,826	5,001	250,506	Feb 09 04:06 PM
Norrett Kevin	Officer	Feb 06 '26	Proposed Sale	1.27	3,291	4,180		Feb 06 06:18 PM
Lutz Stefan	Officer	Feb 06 '26	Proposed Sale	1.27	2,460	3,124		Feb 06 06:15 PM
KEVIN NORRETT	Officer	Jan 16 '26	Proposed Sale	1.67	1,745	2,914		Jan 16 05:09 PM
Lutz Stefan	CSO	Jan 07 '26	Sale	1.70	4,685	7,950	138,775	Jan 08 06:51 PM
Norrett Kevin	Officer	Jan 07 '26	Proposed Sale	1.70	6,123	10,409		Jan 07 09:17 PM
Opaleye Management Inc.	10% Owner	Dec 01 '25	Sale	1.67	253,533	422,766	179,989	Dec 01 05:41 PM
Opaleye Management Inc.	10% Owner	Nov 28 '25	Sale	1.75	107,490	188,108	188,522	Dec 01 05:41 PM
Opaleye Management Inc.	10% Owner	Nov 26 '25	Sale	1.74	5,000	8,706	191,012	Dec 01 05:41 PM
WOLF DENNIS P	Director	Nov 21 '25	Sale	1.56	8,952	13,988	138,951	Nov 25 04:18 PM
DENNIS P WOLF	Officer	Nov 21 '25	Proposed Sale	1.56	8,952	13,988		Nov 21 04:51 PM
Opaleye Management Inc.	10% Owner	Nov 12 '25	Sale	1.96	192,459	376,924	196,012	Nov 14 04:15 PM
De Vre Raymond	Director	Nov 11 '25	Sale	1.74	1,413	2,459	87,416	Nov 13 04:16 PM
Opaleye Management Inc.	10% Owner	Nov 11 '25	Sale	1.80	548,211	986,451	223,461	Nov 12 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 10 '25	Sale	1.73	208,318	361,369	236,682	Nov 12 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 07 '25	Sale	1.70	10,000	16,968	240,000	Nov 12 04:05 PM
MOORE ALISON	Chief Technical Officer	Oct 13 '25	Sale	2.51	6,239	15,629	169,332	Oct 15 05:14 PM
Erbez Georgia	Chief Financial Officer	Oct 13 '25	Sale	2.50	6,239	15,629	70,636	Oct 15 05:13 PM
Erbez Georgia	Officer	Oct 13 '25	Proposed Sale	2.51	6,239	15,629		Oct 14 05:08 PM
MOORE ALISON	Officer	Oct 13 '25	Proposed Sale	2.51	6,239	15,630		Oct 14 05:00 PM
Opaleye Management Inc.	10% Owner	Jul 31 '25	Buy	2.68	84,220	225,710	12,544,220	Aug 04 04:38 PM
Opaleye Management Inc.	10% Owner	Aug 04 '25	Buy	2.83	780	2,211	12,545,000	Aug 04 04:38 PM
Opaleye Management Inc.	10% Owner	Jul 29 '25	Buy	2.82	8,422	23,750	12,458,422	Jul 31 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 30 '25	Buy	2.79	1,578	4,411	12,460,000	Jul 31 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 18 '25	Buy	2.82	100,000	282,000	12,450,000	Jul 22 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 27 '25	Buy	2.39	100,000	239,000	12,350,000	Jul 01 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 12 '25	Buy	2.25	100,000	225,000	12,100,000	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	Jun 13 '25	Buy	2.23	99,102	220,997	12,199,102	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	Jun 16 '25	Buy	2.24	50,898	114,012	12,250,000	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	May 23 '25	Buy	2.36	2,320,000	5,475,200	11,995,000	May 28 04:05 PM
Opaleye Management Inc.	10% Owner	May 28 '25	Buy	2.36	5,000	11,800	12,000,000	May 28 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 30 '25	Buy	2.31	25,000	57,660	9,655,000	May 02 04:05 PM
Opaleye Management Inc.	10% Owner	May 01 '25	Buy	2.32	20,000	46,436	9,675,000	May 02 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 25 '25	Buy	2.24	25,000	55,915	9,630,000	Apr 29 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CDXS

Codexis Inc

Upgrade your Finviz experience